NASA Logo

NTRS

NTRS - NASA Technical Reports Server

Back to Results
Population Pharmacokinetics of Intranasal ScopolamineIntroduction: An intranasal gel dosage formulation of scopolamine (INSCOP) was developed for the treatment of Space Motion Sickness (SMS).The bioavailability and pharmacokinetics (PK) was evaluated using data collected in Phase II IND protocols. We reported earlier statistically significant gender differences in PK parameters of INSCOP at a dose level of 0.4 mg. To identify covariates that influence PK parameters of INSCOP, we examined population covariates of INSCOP PK model for 0.4 mg dose. Methods: Plasma scopolamine concentrations versus time data were collected from 20 normal healthy human subjects (11 male/9 female) after a 0.4 mg dose. Phoenix NLME was employed for PK analysis of these data using gender, body weight and age as covariates for model selection. Model selection was based on a likelihood ratio test on the difference of criteria (-2LL). Statistical significance for base model building and individual covariate analysis was set at P less than 0.05{delta(-2LL)=3.84}. Results: A one-compartment pharmacokinetic model with first-order elimination best described INSCOP concentration ]time profiles. Inclusion of gender, body weight and age as covariates individually significantly reduced -2LL by the cut-off value of 3.84(P less than 0.05) when tested against the base model. After the forward stepwise selection and backward elimination steps, gender was selected to add to the final model which had significant influence on absorption rate constant (ka) and the volume of distribution (V) of INSCOP. Conclusion: A population pharmacokinetic model for INSCOP has been identified and gender was a significant contributing covariate for the final model. The volume of distribution and Ka were significantly higher in males than in females which confirm gender-dependent pharmacokinetics of scopolamine after administration of a 0.4 mg dose.
Document ID
20130013380
Acquisition Source
Johnson Space Center
Document Type
Conference Paper
Authors
Wu, L.
(Houston Univ. Houston, TX, United States)
Chow, D. S. L.
(Houston Univ. Houston, TX, United States)
Putcha, L.
(NASA Johnson Space Center Houston, TX, United States)
Date Acquired
August 27, 2013
Publication Date
January 1, 2013
Subject Category
Aerospace Medicine
Report/Patent Number
JSC-CN-28713
Meeting Information
Meeting: American Association of Pharmaceutical Scientists (AAPS)Annual Meeting
Location: San Antonio, TX
Country: United States
Start Date: November 10, 2013
End Date: November 14, 2013
Sponsors: American Association of Pharmaceutical Scientists
Distribution Limits
Public
Copyright
Public Use Permitted.
No Preview Available